RAMSAY SANTE : résultats annuels définitifs à fin juin 2026

For the year ended June 30, 2026, Ramsay Santé revenue rose 3.3% to €5.381bn and EBITDA increased 2.6% to €637.7m, with the EBITDA margin holding at 11.9%; the €48.3m net loss attributable to the Group narrowed from €54.1m. Operating cash flow fell €169m to €524.7m, largely as working capital normalized, while adjusted net leverage remained 4.7x. The company targets about 3% annual revenue growth through 2029, progressive margin improvement and adjusted net leverage below 4.0x; it also completed a €1.75bn senior debt refinancing and will not propose a dividend for the year.

Analysis

The investment case is primarily a cash-conversion and capital-structure story, not an acceleration story. Organic growth and flat reported EBITDA margin leave little evidence yet that “Connecting Care 2030” can overcome public reimbursement lag and medical-staff inflation; the digital/productivity ambition is not quantified. The FY29 revenue trajectory is only modestly above current organic growth, so execution must show up in margin expansion and lower leverage to support re-rating.

The working-capital reversal partly reflects prior-year timing benefits, so the cash-flow decline is not a clean read-through to recurring operations. But recurring cash is still heavily competed for by interest, lease payments and investment: asset sales and sale-leasebacks provide liquidity, not operating deleveraging. The 4.7x pre-IFRS leverage and continuing net loss make the sub-4x target execution-sensitive. July’s refinancing extends maturities and accommodates the proposed Ramsay Health Care distribution, but the disclosed E+350bp/99 OID terms underline that flexibility is not free.

Near term, the proposed 52.79% distribution and ASX CDI admission create a potential ownership and liquidity reset: broader access may improve discovery, while recipient selling or uncertainty around settlement can weigh on the shares. Neither outcome is assured until approvals, mechanics and any index effects are known. The St. Göran contract supports revenue visibility, but its headline contract value is not a proxy for incremental profit; verify margins and cash requirements as operations ramp. FX also inflated Nordic reported growth and can reverse.

Contrarian point: normalized working capital could make next-year cash conversion look better without equivalent EBITDA acceleration. Treat any early cash-flow rebound cautiously; the durable rerating trigger is margin improvement alongside falling pre-IFRS leverage.

Key Decisions for Investors

• Keep GDS on event watch rather than initiate an outright position before the Ramsay Health Care distribution timetable, CDI conversion terms, expected free float and likely recipient selling are clarified. Reassess after the distribution mechanics are published.
• For a 1–3 month catalyst, track quarterly organic growth, EBITDA margin and working-capital cash flow separately from FX and asset-sale proceeds. A margin step-up with positive underlying cash conversion would support a long thesis; flat margins or another decline in cash balances would argue against it.
• Do not treat the St. Göran contract headline as an earnings catalyst without evidence of contribution margin and cash needs. Watch contract-level profitability and Nordic organic growth excluding currency; weakening volumes or adverse FX would falsify the assumed support.
• Use pre-IFRS net leverage below 4.0x as the medium-term thesis test. If leverage remains near 4.7x despite reported EBITDA growth, or productivity gains fail to outpace wage and consumables inflation, avoid adding exposure; refinancing maturity extension alone is not deleveraging.